

Noxafil (posaconazole) oral suspension, packet, tablets
Effective 07/01/2023

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Posaconazole is an antifungal medication that interferes with fungal cytochrome P450 (lanosterol-14 α -demethylase) activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting fungal cell membrane formation.

Coverage Guidelines

Authorization for Noxafil will be granted for members who are at least 13 years of age and meet **ALL** of the following diagnosis-specific criteria (where appropriate) and documentation has been provided:

1. Zygomycosis (mucormycosis)
2. Prevention of invasive aspergillus and candida fungal infection
 - The member has a diagnosis of a hematologic malignancy with neutropenia or graft-versus-host-disease or has undergone a hematopoietic stem cell transplant
3. Esophageal candidiasis
 - a) The request is for the oral suspension
 - b) The member has had an inadequate response, intolerance or has a contraindication to all of the following:
 - Oral fluconazole
 - Itraconazole
 - Voriconazole
4. Oropharyngeal candidiasis
 - a) The request is for the oral suspension
 - b) The member has had an inadequate response, intolerance or has a contraindication to both:
 - Oral fluconazole
 - Itraconazole

Limitations

Authorizations will be approved for 3 months. Except when being prescribed by an infectious disease (ID) specialist or a hematology/oncology specialist, then approvals will be granted up to 6 months.

References

1. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc; March 2020

2. US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated September 24, 2015. Accessed September 25, 2015
3. Oude Lashof AM, De Bock R, Herbrecht R, et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. *Eur J Cancer* 2004; 40:1314.
4. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. *Clin Infect Dis* 2007; 44:607
5. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007; 356:335
6. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016; 63: e1
7. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;62(4):e1-e50. [PubMed 26679628]
8. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clin Infect Dis* 2006; 42: e61
9. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; 356:348
10. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. *J Clin Oncol* 2018; 36:3043
11. Gebremariam T, Alkhazraji S, Baldin C, et al. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. *Antimicrob Agents Chemother* 2017; 61

Review History

01/01/2018 – Implemented

09/18/2017 – Reviewed

09/18/2019 – Reviewed

09/16/2020 – Reviewed and Updated Sept P&T; added Zygomycosis and Oropharyngeal candidiasis diagnosis per package insert and FDA; references updated. Effective 12/01/2020.

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

04/12/2023 – Reviewed and Updated for April P&T; added new formulation of Noxafil oral packet to criteria. Effective 7/1/2023

10/11/2023 – Reviewed and Updated for Oct P&T; no clinical changes. Added Noxafil oral packets to header.

